Medpage Today on MSN15h
Risk-Reducing Surgery May Benefit BRCA Carriers With Early-Onset Breast CancerAmong more than 5,000 patients followed for a median of roughly 8 years, bilateral risk-reducing mastectomy (RRM) was ...
Breast cancer patients aged 40 or younger with BRCA mutations had a 35% lower risk of death and 42% lower risk of cancer ...
Patients with high-risk, BRCA-positive breast cancer who received olaparib (Lynparza) after standard treatment continued to ...
Patients with germline BRCA mutations who were diagnosed with breast cancer at or before age 40 and who underwent a bilateral ...
AstraZeneca and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced long-term results ...
Patients with high-risk, BRCA-positive breast cancer who received olaparib after standard treatment continued to have better ...
Patients with high-risk, BRCA-positive breast cancer who received olaparib (Lynparza) after standard treatment continued to have better survival outcomes than those who received placebo after a median ...
Patients with germline BRCA mutations who were diagnosed with breast cancer at or before age 40 and who underwent a bilateral risk-reducing mastectomy (RRM) and/or a risk-reducing ...
Patients with germline BRCA mutations who were diagnosed with breast cancer at or before age 40 and who underwent a bilateral ...
The rates of late-stage breast cancer at diagnosis have risen among women in all racial and ethnic groups, but Black women ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback